



Board Certification:

American Board of Internal Medicine: #068744 9/78  
American Board of Gastroenterology: #068744 11/83

Research Certification:

Academy of Pharmaceutical Physicians and Investigators  
(APPI) Certified Physician Investigator 9/09  
NIH Clinical Research Training Certification 5/09

Professional Society Membership:

American College of Physicians  
American Gastroenterological Association  
American Federation for Clinical Research  
Alpha Omega Alpha  
American Association for the Study of Liver Disease  
American Society for Gastrointestinal Endoscopy  
Gastrointestinal Research Group  
American College of Gastroenterology  
Sphincter of Oddi Society  
Elected Fellow - American College of Physicians 4/82  
Elected Fellow - American College of Gastroenterology  
European Association for the Study of Liver 12/13

HONORS AWARDS:

NSF Summer Research Fellowship - 1969  
Summa cum laude, Univ California, Irvine - 1971  
Honors in Biology, Univ California, Irvine - 1971  
3 Years Track to Graduation, Univ California, Irvine,  
California College of Medicine  
University of Colorado Department of Medicine Research  
Project Award. March, 1999.  
Peak of Excellence Award - Rocky Mountain Chapter of the  
American Liver Foundation-2012  
Denver Business Journal - Best Gastroenterologist - 2013,  
2014  
5280 Magazine - Top Doc (Gastroenterology) - 2018

COMMITTEES:

Nutrition Subcommittee - Univ Colo Health Sciences Center  
(1982-83), (May, 1985-86)  
Human Subjects Committee - Univ Colo Health Sciences Center  
(1982-1991)

Human Subjects Committee - Denver VA Hospital (1983-1991)  
Laser Subcommittee - Univ Colo Health Sciences Center  
1983-1991)  
Private Diagnostic Clinic Committee (1984)  
Hospital Marketing Committee (1984)  
Clinical Scholars Committee (1984-1986)  
Credentials Committee University Hospital (1988-1991)  
Research and Development Committee, American Society for  
Gastrointestinal Endoscopy (1988-1990)  
Secretary, Colorado-Wyoming Enterologic Society(1988-  
President,Colorado-Wyoming Enterologic Society (1992-  
1994)1999-xx)  
University of Colorado Health Sciences Center Faculty  
Senate (1988-1990)  
Quality Assurance Committee Poudre Valley  
Hospital(1992,1993)  
Governor, American College of Gastroenterology, state of  
Colorado - 10/91. Reelected - 10/93, 10/95  
Regional Councilor for Region V - American College of  
Gastroenterology - 10/92, 10/93 & 11/94  
Editorial Board - American Journal of  
Gastroenterology(1991-2000)  
American College Gastroenterology, Public Relations  
Committee (1994-1999)  
American College Gastroenterology, Nominating Committee  
1994-1996)  
Clear Creek Valley Medical Society, Third Party Payer  
Committee (1995-1996)  
Clear Creek Valley Medical Society, Grievance Committee  
1996-1999) Chairman 1999  
American Liver Foundation, Colorado Branch - President,  
Board of Directors (1997-2000) board member currently  
Centura-St. Anthony Hospitals, Investigational Review  
Board (1998-2005)- Chairman, 5/99 to 2005.  
Rocky Mountain Gastroenterology Associates - Board of  
Managers (1/00 to 1/02)  
Centura-St. Anthony Central Hospital, Medical Executive  
Committee (7/10 - 7/20)  
Rocky Mountain Clinical Research, Board of Directors,  
January, 2009 - 2019.  
American liver Foundation National Medical Advisory Board,  
2013 - present.  
Rocky Mountain Clinical Research, President of Board,  
February, 2014 - 2019.  
Governor, American College of Gastroenterology, state of  
Colorado - October 2011 - 2017.  
Re-elected October 2023 - present  
Colorado Gastrointestinal Pathology (CGIP) - Board of

Directors, January, 2014 - December 2015.

HOSPITAL AFFILIATIONS:

Centura - St. Anthony Hospital - Lakewood, CO  
Exempla - Lutheran Medical Center - Wheat Ridge, CO  
HealthOne - Medical Center of Aurora - Aurora, CO  
HealthOne - Presbyterian-St. Lukes Medical Center -  
Denver, CO  
Peak One Surgery Center and Summit Medical Center  
- Frisco, CO  
OrthoColorado Hospital - Lakewood, CO  
Vail Valley Medical Center and Surgery Center - Edwards, CO  
Parkview Hospital - Pueblo, CO

PUBLICATIONS:

1. Brugge WR, Goff JS, Allen NC, Podell ER and Allen RH. Development of a dual-label Schilling Test for pancreatic exocrine function based on the differential absorption of cobalamin bound to intrinsic factor and R-protein. Gastroenterology 1980;78:937.
2. Goff JS, Thompson JS, Pratt CF, Tomasso GI, Penn I. Jejunal rupture caused by a Sengstaken Blakemore tube. Gastroenterology 1982;82:573-575.
3. Goff JS. A two-stage triolein breath test differentiates pancreatic insufficiency from other causes of malabsorption. Gastroenterology 1982;83:44.
4. Goff JS, Feinberg LE, Brugge WR. A randomized trial comparing cimetidine to nasogastric suction in acute pancreatitis. Dig Dis Sci 1982;27:1085.
5. Ayres SJ, Goff JS, Warren GH, Schaefer JW. Esophageal ulceration and bleeding after flexible fiberoptic esophageal vein sclerosis. Gastroenterology 1982;83:131.
6. Goff JS. The non-operative widening of obstructed gastroplasties with a papillotome. Gastrointest Endosc 1984;30:32-34.
7. Ayres SJ, Goff JS, Warren GH. Endoscopic sclerotherapy for bleeding esophageal varices: effects and complications. Ann Intern Med 1983;98:900-903.
8. Fausel CS, Goff JS. Non-operative management of acute idiopathic

colonic pseudo-obstruction (Ogilvie's syndrome). West J Med 1985;143:50-54.

9. Horton ML, Goff JS. Surgical treatment of nutcracker esophagus: A case report. Dig Dis Sci 1986;31:878-883.

10. Goff JS, Adcock KA, Schmelter R. Detection of esophageal ulcerations with <sup>99m</sup>Tc-albumin-sucralfate. J Nucl Med 1986;27:1143-1146.

11. Goff JS. Bipolar coagulation vs Neodymium-YAG laser treatment of upper gastrointestinal bleeding. Dig Dis Sci 1986;31:906-910.

12. Perino LE, Gholson CF and Goff JS. Esophageal perforation following fiberoptic variceal sclerotherapy. J Clin Gastroentol 1987;9:286-289.

13. Stiegmann GV and Goff JS. An alternative to Roux-en-Y for treatment of bile reflux gastritis. Surg Gynecol Obstet 1988;166:69-70.

14. Perino LE, Adcock KA, Goff JS. Gastrointestinal symptoms, motility, and transit following the Roux-en-Y operation. Am J Gastroentol 1988;83:380-5.

15. Stiegmann GV and Goff JS. Endoscopic esophageal varix ligation (EVL): preliminary clinical experience. Gastrointest Endos 1988;34:113-17.

16. Stiegmann G, Goff JS, VanWay C, Perino LE, Pearlman N, Norton L. Operative vs endoscopic gastrostomy: preliminary results of a prospective controlled trial. Am J Surg 1988;155:88-91.

17. Goff JS, Reveille RM and Stiegmann GV. The effect of endoscopic sclerotherapy and endoscopic variceal ligation on esophageal motility. American Journal of Gastroenterology 1988;83:1240-4.

18. Stiegmann GV, Goff JS, Sun JH, Davis D, and Silas D. Technique and early clinical results of endoscopic variceal ligation (EVL). Surg Endosc 1989;3:73-8.

19. Stiegmann GV, Goff JS, Sun JH, and Wilborn S. Endoscopic elastic band ligation for active variceal hemorrhage. Am Surg 1989;55:124-8.

20. Stiegmann GV, Pearlman NW, Goff JS, Sun JH, and Norton LW. Endoscopic cholangiography and stone removal prior to cholecystectomy: A more cost effective approach than operative

duct exploration. Archives Surg 1989;124:787-90.

21. Stiegmann GV, Goff JS, Sun JH, Hruza D, and Reveille M. Endoscopic ligation of esophageal varices. Am J Surg 1990;159:21-6.

22. Stiegmann GV, Goff JS, Silas D, Pearlman N, Sun J, and Norton L. Endoscopic versus operative gastrostomy: Final results of a prospective randomized trial. Gastrointestinal Endoscopy 1990;36:1-5.

23. Stiegmann GV, Goff JS, Sun JH, Davis D, and Bozdech J. Endoscopic variceal ligation: an alternative to sclerotherapy. Gastrointest Endosc 1989;35:431-4.

24. Durham JD, Kumpe DA, Stiegmann GV, Goff JS, Subber SW, and Rothbarth LJ. Direct mesenteric vein catheterization: a combined surgical and radiologic approach to variceal hemorrhage. Radiology 1990;177:229-33.

25. Lewis FW, Warren GH, and Goff JS. Collagenous colitis with involvement of the terminal ileum. Dig Dis Sci 1991;36:1161- 3.

26. VA Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease - a randomized, single blind, multicenter clinical trial. NEJM 1991;324:1779-84.

27. Ready JB, Robertson AD, Goff JS, and Rector WG. Assessment of the risk of bleeding from esophageal varices by continuous monitoring of portal pressure. Gastroenterology 1991;100:1403-10.

28. Reveille RM, Goff JS, and Hollstrom-Tarwater K. The effect of intravenous diazepam on esophageal motility in normal subjects. Digestive Diseases and Sciences 1991;36:1046-9.

29. Leff JA, Ready JB, Repetto C, Goff JS, and Schwarz MI. Coexistence of primary biliary cirrhosis and sarcoidosis. Western J Med 1990;153:439-41.

30. Bell RCW, Stiegmann GV, Goff JS, Reveille M, Norton L, and Pearlman NW. Decision for surgical management of perforation following endoscopic sphincterotomy. American Surgeon 1991;57:237-40.

31. Stiegmann GV, Mansour MA, Goff JS, and Pearlman NW. Roux-en-Yjejunodoudenostomy for endoscopic access to hepaticojejunostomy. Surg Gyn and Obstetrics 1991;173:153-4.

32. Goff JS, Reveille RM, and Stiegmann GV. Three years experience with endoscopic variceal ligation (EVL) for treatment of bleeding varices. *Endoscopy* 1992;24:401-4.
33. Spechler SJ and the Cooperative Group Studies Program #277. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease. *NEJM* 1992;326:786-92.
34. Lewis FW, Moloo N, Stiegmann GV, and Goff JG. Splenic injury complicating therapeutic upper gastrointestinal endoscopy and endoscopic retrograde cholangiography. *Gastrointestinal Endoscopy* 1991;37:632-3.
35. Stiegmann GV, Goff JG, Mansour A, Pearlman N, Reveille RM and Norton L. Pre-cholecystectomy endoscopic cholangiography and stone removal is not superior to cholecystectomy, cholangiography and common duct exploration. *Am J Surg* 1992;163:227-30.
36. Stiegmann GV, Goff JS, Michaletz-Onody PA, Korula J, Lieberman D, Saeed ZA, Reveille RM, Sun JH, and Lowenstein. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. *NEJM* 1992;326:1527-32.
37. Goff JS. The effect of ethanol on the pancreatic duct sphincter of Oddi. *American Journal of Gastroenterology* 1993;88:656-60.
38. Stiegmann GV, Yamamoto M, Goff JS, Reveille RM. Technique and current results of endoscopic variceal ligation. 1991;39:11-16.
39. McNally PR, Lemon JC, Goff JS, and Freeman SR. Congenital esophageal stenosis presenting as noncardiac, esophageal chest pain. *DDS* 1993;38:369-73.
40. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: Results of a randomized, multicenter trial. *Hepatology* 1994;20:618-25.
41. The Flumazenil in Intravenous Conscious Sedation with Diazepam Study Group I. Reversal of central benzodiazepine effects by flumazenil after conscious sedation produced by intravenous diazepam. *Clinical Therapeutics* 1994.
42. Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P, and Lansoprazole Study Group. Double-blind comparison of lansoprazole, ranitidine and placebo in the treatment of acute duodenal ulcer. *American Journal Gastroenterology* 1994;89:1191-1200.

43. Goff JS. Common bile duct pre-cut sphincterotomy: trans-pancreatic sphincter approach. *Gastrointestinal Endoscopy* 1995;41:502-5.
44. Goff JS. Common bile duct sphincter of Oddi stenting in patients with suspected sphincter dysfunction. *Am J Gastroent* 1995;90:586-9.
45. Kozarek RA, Payne M, Barkin J, Goff J, Gostout C. Prospective multicenter evaluation of an initially placed button gastrostomy. *Gastrointestinal Endoscopy* 1995;41:105-8.
46. Goff JS. The effect of propofol on the human sphincter of Oddi. *Dig Dis Sci* 1995;40:2364-7.
47. Lindsey KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perillo RP, Tamburro CH, Goff JS, Everson GT, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. *Hepatology* 1996;24:1034-40.
48. Saeed ZA, Stiegmann GV, Ramirez FC, Reveille RM, Goff JS, Hepps, Cole RA. Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial. *Hepatology* 1997;25:71-4.
49. Hartigan PM, Gebhard RL, Gregory PB and The Veterans Affairs Cooperative Variceal Sclerotherapy Study Group. Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis. *Gastrointestinal Endoscopy* 1997;46:1-7.
50. Ryan ME, Geenen JE, Lehman GA, Aliperti GP, Freeman ML, Silverman WB, Mayeux GP, Frakes JT, Parker HW, Yakshe PN, Goff JS. Endoscopic intervention for biliary leaks following laparoscopic cholecystectomy: a multicenter review. *Gastrointestinal Endoscopy* 1998;47:261-6.
51. Lanza F, Goff J, Silvers D, Winters J, Jhala N, Jennings D, Greski-Rose P and The Lansoprazole Study Group. Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. *Dig Dis Sci* 1997;42:2529-36.
52. Goff JS. Lansoprazole: a cause for secretory diarrhea. *Am J Gastroenterology* 1998;93:2298-9.
53. Goff JS. Long-term experience with the transpancreatic sphincter pre-cut approach to biliary sphincterotomy. *Gastrointestinal*



Endoscopy 1999;50:642-5.

54. Goff JS, Reveille RM, Johnson J. Treatment of Chronic Hepatitis C with Amantadine. *Dig Dis Sci* 2000;45:1389-91.

55. Yacyshyn BR, Chey WY, Goff J, et al. Double-blind, placebo-controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302) in active, steroid-dependent Crohn's disease. *Gut*, 2002;1:36-41.

56. 56. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (Interleukin-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. *Aliment Pharmacol Ther* 2002;16:1761-70.

57. Tiadafilopoulos G, DiBaise JK, Nostrant TT, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial. *Gastrointest Endosc* 2002;55:149-56

58. Sherman S, Blaut U, Watkins JL, et al. Does prophylactic steroid administration reduce the risk and severity of post-ERCP pancreatitis: Randomized prospective multicenter trial. *Gastrointestinal Endoscopy*, 2003;58, 23-9

59. Wood C, Salamo GJ, Goff J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. *Gastrointest Endosc* 2003;58:23-9.

60. Mosler P, Sherman S, Marks J, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. *Gastrointest Endosc* 2005;62:245-50

61. Cheng CL, Sherman S, Watkins JL, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *Am J Gastroenterol* 2006;101:139-47.

62. Deenadayalu VP, Blaut U, Watkins JL, et al. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis: a retrospective, multicenter study? *J Clin Gastroenterol*, 2008;42:1103-9.

63. Rex DK, Deenadayalu VP, Eid E, et al. Endoscopist-directed administration of propofol: a worldwide safety experience. *Gastroenterology* 2009;137:1229-37.

64. Waters H, Vanderpoel J, McKenzie S, et al. Stability of infliximab dosing in inflammatory bowel disease: results from a

multicenter US chart review. J Medical Economics 2011;14:397-402.

65. Waters H, Vanderpoel J, McKenzie S, et al. Resource utilization in patients with inflammatory bowel disease before and during infliximab therapy. J Medical Economics 2011;15:45-52.

BOOK CHAPTERS:

1. Goff JS. Gastrointestinal Diseases in Current Medical Therapy. RW Schrier, ed. Raven Press, NY, 1984. pp 235-263.

2. Goff JS. Nutrition in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1985. pp 2-11.

3. Goff JS. Clinical Utility of Procedures in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1985. pp 12-25.

4. Goff JS. Systemic Diseases and the Gastrointestinal Tract in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1985. 118-125.

5. Goff JS. Diseases of the Pancreas in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, inc., Toronto, 1985. pp 182-199.

6. Goff JS. Diseases of the Abdominal Vasculature and Support Tissues in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1985. pp 302-311.

7. Goff JS. Infections of the Esophagus in Pediatric Gastrointestinal Disease. WA Walker et al, ed. B.C. Decker, Inc., Philadelphia, 1991. pp 386-392. Revised for second edition 1995.

8. Goff JS. Nutrition in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1992. pp 2-21.

9. Goff JS. Clinical Utility of Procedures in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1992. pp 22-43.

10. Goff JS. Diseases of the Pancreas in Decision Making in Gastroenterology. JS Levine, ed. B.C. Decker, Inc., Toronto, 1992. pp 256-279.

11. Goff JS and Levine JS. Systemic Disease of the Gastrointestinal Tract in Decision Making in Gastroenterology. JS Levine, ed. B.C.

Decker, Inc., Toronto, 1992. pp 168-185.

12. Goff JS. The Pharmacology of the Human Sphincter of Oddi. Gastrointestinal Endoscopy Clinics of North America, 1993;3:143-154.

13. Goff JS. Gastroesophageal Varices: Pathogenesis and Therapy of Active Bleeding. Gastroenterology Clinics of North America, 1993;22:779-800.

14. Goff JS. Sclerotherapy and Banding of Esophageal Varices in Current Therapy in Gastroenterology and Liver Disease. Fourth Edition. TM Bayless, ed. Mosby-Year Book, Inc., St. Louis, 1994. pp 73-76.

15. Goff JS. Esophageal Varices. Gastrointestinal Endoscopy Clinics of North America, 1994;4:747-771.

16. Goff JS. Endoscopic Variceal Ligation in Portal Hypertension Falk Symposium #79. A Holstege, EG Hahn, and J Scholmerich, ed. Kluwer Academic Publishers, Lancaster, UK, 1995. pp 321 -327.

17. Stiegmann GV and Goff JS. Complications of Endoscopic Sclerotherapy and Endoscopic Variceal Ligation in Complications in Surgical Endoscopy. J Ponsky, ed. 1996.

18. Goff JS. Malabsorption and Maldigestion in GI/Liver Secrets. PR McNally, ed. Hanley and Belfus, Inc., Philadelphia, 1996. pp 427-433.

19. Goff JS. Colitis: Radiation, Microscopic, Collagenous, and Pseudomembranous in GI/Liver Secrets. PR McNally, ed. Hanley and Belfus, Inc., Philadelphia, 1996. pp 344-350.

20. Goff JS. Per-oral Colonoscopy: Technique, Depth, and Yield of Lesions. Gastrointestinal Endoscopy Clinics of North America, 1996;6:1-6.

21. Goff JS. Endoscopic Management of Variceal Bleeding in Handbook of Gastrointestinal Endoscopy. J Van Dam and RCK Wong, eds. 1999.

22. Goff JS. Bleeding Esophageal Varices in Conn's Current Therapy. Robert E. Rakel, M.D. editor. W.B. Saunders Co. 2000.

23. Goff JS. Upper Gastrointestinal Tract Hemorrhage in GI/Liver Secrets. PR McNally, ed. Hanley and Belfus Inc., Philadelphia, 2001, 2005, 2009 (Chapter 55)

24. Goff JS. Occult and Obscure Gastrointestinal Bleeding in

GI/Liver Secrets. PR McNally, ed. Hanley and Belfus Inc., Philadelphia, 2001, 2005, 2009 (Chapter 57)

25. Goff JS. Question 7 - Bleeding Varices in Curbside Consultation in Gastroenterology. Joseph Leung and Simon Lo, ed. SLACK Incorp. Thorofare, NJ, 2009.

26. Goff JS. Evaluation of Acute Abdominal Pain in GI/Liver Secrets. PR McNally, ed Hanley and Belfus Inc., Philadelphia, 2014 (Chapter 54)

ABSTRACTS:

1. Goff JS, Goff M, Brugman T, Arquilla E. The induction of experimental diabetes with insulin antibodies against a restricted determinant. *Excerpta Medica* 1973;280:131.

2. Goff JS, Goff M, Brugman T, Arquilla E. The induction of diabetes with insulin antibodies against a restricted determinant. *Fed Proc* 1973;32:311.

3. Goff JS, Feinberg LE, Brugge WR. Randomized trial comparing cimetidine to nasogastric suction in acute pancreatitis. *Gastroenterology* 1981;80:1158.

4. Goff JS. A two stage triolein breath test separates pancreatic insufficiency from other causes of malabsorption. *Gastroenterology* 1981;80:1158.

5. Ayres S, Goff JS Warren G. Autopsy findings after esophageal vein sclerosis. *Gastroenterology* 1982;82:1011.

6. Fausel CS, Goff JS. Outcome of medical therapy and colonoscopy in acute colonic pseudo-obstruction (Ogilvie's syndrome). *Gastroenterology* 1983;84:1148.

7. Horton ML, Goff JS. Surgical treatment of nutcracker esophagus: A case report. *Society of Air Force Physicians*, October, 1983.

8. Goff JS. Diabetic diarrhea: A multifactorial disorder. *Gastroenterology* 1984;86:1091.

9. Goff JS. Bipolar coagulation vs Neodymium-YAG laser treatment of upper gastrointestinal bleeding. *Lasers Surg Med* 1985;5:187.

10. Goff JS, Adcock K, Schmelter R. Detection of esophagitis with <sup>99m</sup>Tc-albumin-sucrafate (Tc-Su. *Gastroenterology* 1985;88:1397.

11. Stiegmann G, Cambre A, Sun J, Goff J. Cost of effective endoscopic cholangiography and stone removal prior to cholecystectomy. *Gastroenterology* 1986;90:1649.
12. Perino LE, Goff JS. Reproducibility of 24-hour ambulatory esophageal pH monitoring in normal subjects. *Gastroenterology* 1986;90:1583.
13. Goff JS, Ayres SJ, Hollstrom-Tarwater K. A randomized trial of sclerotherapy vs standard therapy for bleeding esophageal varices. *Gastroenterology* 1986;90:1728.
14. Goff JS for the Lidamide-HCl IBS Study Group. Lidamide-HCl reduces pain in irritable bowel syndrome: A multicenter, double-blind study. *Gastroenterology* 1986;90:1429.
15. Goff JS, Lamon KD. Lidamide-HCl decreases pain in irritable bowel syndrome: A multicenter, double-blind trial. *Dig Dis Sci* 1986;31:25s.
16. Perino LE, Goff JS. Effect of sclerotherapy on ascitic fluid parameters. *Hepatology* 1986;6:1179.
17. Stiegmann G, Goff J, VanWay C, Perino L, Pearlman N, Norton L. Operative vs endoscopic gastrotomy: Preliminary results of a prospective randomized trial. Presented: Society for Surgery of the Alimentary Tract meeting, Chicago, IL, May, 1987.
18. Stiegmann, Goff JS. Endoscopic variceal ligation: Preliminary clinical experience. *Gastrointest Endosc* 1987;33:155.
19. Goff JS, Perino LE, Adcock KA. Gastrointestinal symptoms, motility, and transit in patients with a Roux-en-Y. *Gastroenterology* 1987;92:1407.
20. Gregory P, Hartigan P, Amodeo D, Baum R, Camara D, Colcher H, Fye C, Gebhard R, Goff J, et al. Prophylactic sclerotherapy for esophageal varices in alcoholic liver disease: Results of a VA cooperative randomized trial. *Gastroenterology* 1987;92:1414.
21. Goff JS, Stiegmann GV. Endoscopic variceal ligation: A new method for treating esophageal varices. *Am J Gastroenterology* 1987;82:968.
22. Goff JS, Stiegmann GV, Hollstrom-Tarwater K, Aguayo M. The effects of sclerotherapy vs endoscopic variceal ligation on the esophagus and esophageal varices. *Hepatology* 1987;7:1062.

23. Stiegmann GV, Goff JS, Sun JH. Endoscopic esophageal varix ligation in acute variceal hemorrhage. *Hepatology* 1987;7:1062.
24. Stiegmann G, Goff J, Sun J, Wilborn S. Endoscopic elastic band ligation for active variceal hemorrhage. *Am Surg* 1988;54:528.
25. Goff JS, Hollstrom-Tarwater K. The effect of ethanol on the pancreatic duct sphincter of Oddi. *Gastrointest Endosc* 1988;34:108.
26. Reveille M, Goff JS, Hollstrom-Tarwater K. The effect of intravenous diazepam on esophageal manometry in normal subjects. *Gastroenterology* 1988;34:209.
27. Stiegmann GV, Goff JS, Sun JH, Bozdech J. Endoscopic variceal ligation: A safe and effective alternative to sclerotherapy. *Gastrointest Endosc* 1988;34:209.
28. Goff JS, Stiegmann GV, Sun JH, Zogg DL. Endoscopic variceal ligation (EVL) for elective management of esophageal varices. VI European Congress of Digestive Endoscopy, Rome, 1988.
29. Stiegmann GV, Goff JS, Sun JH, Davis D. Endoscopic ligation of bleeding esophageal varices: A new alternative to sclerotherapy. International Congress on Surgical Endoscopy, Ultrasound and Interventional Techniques. Berlin, West Germany, July, 1988. (journal of same name 1988;2:114)
30. Stiegmann GV, Goff JS, Sun JH, Davis D. The technique of elastic "o" ring endoscopic variceal ligation. *Surgical Endoscopy, Ultrasound, and Interventional Techniques* 1988;2:123.
31. Goff JS, Stiegmann GV. Esophageal variceal hemorrhage - medical therapy(C) vs sclerotherapy (ES) vs endoscopic variceal ligation (EVL): A retrospective study. *Am J Gastroenterology* 88;83:1063.
32. Stiegmann GV, Goff JS, Sun JH, Hruza D, Reveille RM. Endoscopic ligation of esophageal varices: The first 100 cases. Presented at SSAT, 1989.
33. Stiegmann GV, Kumpe D, Stubber S, Durham J, Goff JS. Mini-lap with angiographic variceal thrombosis for high risk failures of endoscopic ligation. Presented at SSAT, 1989.
34. Stiegmann GV, Goff JS, Silas D, Pearlman N, Sun J, Norton L. Endoscopic vs operative gastrotomy: Final results of a prospective randomized trial. *Gastrointest Endosc* 1989;35:159.
35. Durham JD, Kumpe DA, Stiegmann GV, Goff JS, Stubber SW,

Rothbart. Direct mesenteric vein catheterization: A combined surgical and radiologic approach. Submitted Radiologic Society of North America, 1989.

36. Stiegmann G, Goff J, Michalitz P, Korula J, Lieberman D, Reveille M, SUN J. Endoscopic variceal ligation vs sclerotherapy for bleeding esophageal varices: Early results of a prospective randomized trial. *Gastrointest Endosc* 1990;36:188.

37. Bell RCW, Stiegmann G, Goff J, Pearlman N, Reveille M. Norton L. Decision for surgical management of perforation following endoscopic sphincterotomy (ES). Submitted to SAGES, 1990.

38. Gregory PB and the VA Cooperative Sclerotherapy Study Group. Sclerotherapy for actively bleeding esophageal varices in male alcoholics with cirrhosis: Results of a randomized, multicenter clinical trial. *Gastroenterology* 1990;98:A403.

39. Ahnen DJ, Bunn PA, Doos WG and VA Cooperative Group #277. Aneuploidy and Barrett's esophagus: Data from VA Cooperative Study #277. *Gastroenterology* 1990;98:A15.

40. Spechler SJ, Williford WO and VA Cooperative Study Group #277. A prospective, randomized trial of medical and surgical therapies for gastroesophageal reflux disease (GERD). *Gastroenterology* 1990;98:A129.

41. Spechler SJ, Williford WO and VA Cooperative Study Group #277. Complications of medical and surgical therapies for gastroesophageal reflux disease (GERD). *Gastroenterology* 1990;98:A130.

42. Spechler SJ, Williford WO, Krol WF and VA Cooperative Study Group #277. Development and validation of a gastroesophageal reflux disease activity index (GRACI). *Gastroenterology* 1990;98:A130.

43. Doos WG Spechler SJ, Williford WO and VA Cooperative Study Group #277. Barrett's specialized columnar epithelium: Diagnostic discrepancies. *Gastroenterology* 1990;98:A37.

44. Coley CM, Barry MJ, Mulley AG and VA CSG #277. Medical vs surgical therapy for gastroesophageal reflux disease: A decision analysis. *Gastroenterology* 1990;98:A32.

45. Reveille RM, Goff JS, Stiegmann GV. Initial experience with a combination of endoscopic variceal ligation (EVL) and endoscopic sclerotherapy (ES) for treatment of bleeding varices. World Congress of Gastroenterology, Sidney, Australia, August, 1990.

46. Goff JS, Reveille RM, Sun J, Stiegmann GV. Three years experience with endoscopic variceal ligation (EVL) for treatment of bleeding esophageal varices. World Congress of Gastroenterology, Sidney, Australia, August, 1990.
47. Gregory PB and the VA Cooperative Sclerotherapy Study Group. Sclerotherapy for male alcoholics with cirrhosis who have bled from esophageal varices: Results of a randomized, multicenter clinical trial. World Congress of Gastroenterology, Sidney, Australia, August, 1990.
48. Steigmann G, Goff J, Mansour A, Pearlman N, Reveille M, Norton L. Pre-cholecystectomy endoscopic cholangiography and stone removal (ERCSR) is not superior to cholecystectomy, cholangiography and common duct exploration (CC+CBDE): A prospective, randomized trial. Presented at SSAT, 1991.
49. Reveille RM, Goff JS, Stiegmann GV, Stauffer JT. Combination endoscopic variceal ligation (EVL) and low-volume endoscopic sclerotherapy (ES) for bleeding esophageal varices: a faster route to variceal eradication? *Gastrointestinal Endoscopy* 1991;37:243.
50. Waring JP, Williford WO, Krol WF, Spechler SJ and VA Cooperative Study Group #277. The influence of cigarette smoking on the success of medical and surgical therapy for complicated gastroesophageal reflux disease. *Gastroenterology* 1991;100:A182.
51. Lanspa SJ, Spechler SJ, DeMester WF, Zetterman R, Williford WO, Krol WF, and VA Cooperative Study Group #277. Incidence of esophageal stricture formation in patients with complicated gastroesophageal reflux disease (GERD). *Gastroenterology* 1991;100:A107.
52. Spechler SJ, Williford WO, and VA Cooperative Study Group #277. Medical vs surgical therapy for gastroesophageal reflux disease (GERD). *Gastroenterology* 1991;100:A19.
53. Lanspa SJ, Zetterman R, DeMester TR, Dunnington G, Williford WO, Krol WF, Waring JP, Spechler SJ, and VA Cooperative Study Group #277. Predictors of therapeutic outcome in patients with complicated GERD. *Gastroenterology* 1992;102:A108.
54. Movva R, Shaba B, Jennings D, Levy C, Greski-Rose P, and the Lansoprazole Study Group. Lansoprazole heals gastric ulcers. *Gastroenterology* 1992;102:A129.
55. Robinson M, Kogut D, Jennings, Levy C, Greski-Rose P, and the Lansoprazole Study Group. Lansoprazole heals erosive esophagitis



better than ranitidine. *Gastroenterology* 1992;102:A153.

56. Ferguson DR, Picha G, Wylie R, Goff J, Kelsey P, Robertson E, Salwan F, Iannuccilli E, White J, Marshall J, Kozarek R. Early experience with the Pullwire One Step Button (POSB). *Gastrointestinal Endoscopy* 1993;39:250.

57. Kozarek R, Payne M, Barkin J, Goff J, Gastout C, and GI Section Members. Prospective multicenter trial using one-step gastric button for initial PEG placement. *Gastrointestinal Endoscopy* 1993;39:253.

58. Lindsay KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perrillo R, Tamburro C, Silva M, Goff J, Everson G, Sanghvi B, Albrecht J. Long-term response to higher doses of interferon (IFN) Alpha-2b treatment of patients with chronic hepatitis C: a randomized multicenter trial. *Hepatology* 1993;18:106A.

59. Goff JS. Tachyoddia causing relapsing pancreatitis. *Am J Gastroenterology* 1993;88:1611.

60. Lanza F, Goff J, Silvers D, and the Lansoprazole Study Group. Lansoprazole for one year prevents recurrence of duodenal ulcer disease. *Gastroenterology* 1994;106:A122.

61. Saeed ZA, Stiegmann GV, Ramirez FC, Reveille RM, Goff JS, Heppa KS, Cole RA. Endoscopic variceal ligation versus combined ligation and low dose sclerotherapy: a multicenter randomized trial. *Am J Gastroenterology* 1994;89:1626.

62. Goff JS. The effect of propofol on the human sphincter of Oddi. *Am J Gastroenterology* 1994;89:1654.

63. Goff JS. The role of the sphincter of Oddi (SO) stenting in patients with suspected SO dysfunction. *Am J Gastroenterology* 1994;89:1654.

64. Sherman S, Lehman G, Earle D, Watkins J, Barnett J, Johanson J, Freeman M, Geenen J, Ryan M, Parker H, Lazaridis E, Flueckiger J, Silverman W, Dua K, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J. Does obesity increase the risk and severity of post-ERCP pancreatitis? *Gastrointestinal Endoscopy* 1997;45:AB164.

65. Sherman S, Lehman G, Earle D, Watkins J, Barnett J, Johanson J, Freeman M, Geenen J, Ryan M, Parker H, Lazaridis E, Flueckiger J, Silverman W, Dua K, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *Gastrointestinal Endoscopy* 1997;45:AB165.

66. Sherman S, Lehman G, Earle D, Watkins J, Barnett J, Johanson J, Freeman M, Geenen J, Ryan M, Parker H, Lazaridis E, Fogel E, Flueckiger J, Silverman W, Dua K, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J. Does prophylactic steroid administration reduce the frequency and severity of post-ERCP pancreatitis? Randomized prospective multicenter study. *Gastrointestinal Endoscopy* 1997;45:AB165.
67. Lehman G, Sherman S, Geenen J, Tarnasky P, Goldberg M, Kruse A, Aliperti G, Barnett J, Elta G, Howell D, Goff J, Gottlieb K, Howard T, Madura J, Hawes R. ERCP findings in mucinous/cystic tumors of the pancreas. *Gastrointestinal Endoscopy* 1997;45:AB161.
68. Lehman G, Sherman S, Barnett J, Tarnasky P, Howell D, Aliperti G, Goff J, Hamelman L, Fraiberg E, Yakshe P, Elta G. Intraductal tissue sampling in mucinous and cystic tumors of the pancreas. *Gastrointestinal Endoscopy* 1997;45:AB161.
69. Sherman S, Lehman G, Freeman M, Earle D, Watkins J, Barnett J, Johanson J, Geenen J, Ryan M, Parker H, Lazaridis E, Flueckiger J, Silverman W, Dua K, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *Am J Gastroenterology* 1997;92:1639.
70. Sherman S, Lehman G, Freeman G, Watkins J, Barnett J, Fogel E, Johanson J, Geenen J, Ryan M, Parker H, Lazaridis E, Flueckiger J, Silverman W, Dua K, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *Gastroenterology* 1998;
71. Goff JS. Common bile duct sphincterotomy (transpancreatic sphincter approach): Safety and efficacy. *Am J Gastroenterology* 1998;93:1655.
72. Goff JS, Reveille RM, Johnson J. Treatment of chronic hepatitis C with Amantadine. *Am J Gastroenterology* 1998;93:1675.
73. Mindenhall K, Danhour G, Johnson J, Lewis F, Goff J. Hyperlipasemia and pancreatitis in patients with chronic HCV treated with interferon- $\alpha$  (IFN) and ribavirin. *Hepatology* 1999;29:
74. Shrestha R, Folan R, Goff JS, Anselm K, Trouillot T, McKinley C, Richman L. The Colorado hepatitis treatment group: Interferon-alpha-2b + ribavirin treatment is efficacious in nonresponders to prior interferon monotherapy. *Hepatology* 2000;32:353A.

75. Triadafilopoulos, DiBaise, Nostrant, Stollman, Anderson, Wolfe, Rothstein, Wo, Corley, Patti, Antignano, Goff, Edmundowicz, Castell, Rabine, Utley. Long-term experience with the Stretta procedure: 12 month follow-up of the U.S. open label trial. *Gastrointestinal Endoscopy* 2001
76. Yacyshyn BR, Chey WY, Goff J, et al. A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroid-dependent Crohn's disease showed clinical improvement at high serum levels. *Gastroenterology* 2001;120:A279-80.
77. Sherman, S, et al. Does prophylactic allopurinol administration reduce the frequency and severity of post-ERCP pancreatitis: A randomized prospective multicenter study. *Gastrointestinal Endoscopy* 2002;55:AB154.
78. Barish CF, Goff J, et al. High dose safety and pharmacokinetic study of ISIS 2302 in Crohn's disease. *Am J Gastroenterology* 2002;97:S250.
79. Dalke DD, Donovan J, Goff J, et al. PEG 12000-IFN Alfa 2b 0.5 mcg/kg + ribavirin 800 mg/day vs PEG 12000-IFN Alfa 2b 1.5 mcg/kg + ribavirin 800 mg/day for 48 weeks for treatment of patients with hepatitis C who failed or relapsed after treatment with combination therapy (Rebetron) - interim results. *Hepatology* 2002;36:598A.
80. Goff J, Branch P, and Thomsen L. Hispanic patients have a different response to interferon/ribavirin therapy for hepatitis C than non-Hispanic white patients. *Hepatology* 2004;38:94A.
81. Lawitz E, Nguyen T, Younes Z, et al. Valpicitabine (NM283) plus PEG-interferon in treatment-naïve hepatitis C patients with HCV genotype-1 infections: HCV RNA clearance during 24 weeks of treatment. *Hepatology* 2006;44:223A.
82. Goff J, Jain, R, Branch P, et al. Development and implementation of a nono-anesthesiologist (nurse-based) propofol sedation program for endoscopy at a community hospital. *Am J Gastroenterol* 2006;101:S500
83. Gitlan N, Lawitz E, Nguyen T, et al. Valpicitabine (NM283) plus PEG-interferon alfa-2a (PEG-IFN) in treatment naïve patients with HCV-1 infection: preliminary results at weeks 24 and 48. *Gastroenterology* 2007;132:A780.
84. Deenadayali VP, Eid EF, Goff JS, et al. Non-anesthesiologist administered propofol sedation for endoscopic procedures: a worldwide safety report. *Gastrointest Endosc* 2008;67:AB107.

85. Lawitz E, Box RE, Pruitt M, et al. High rates of rapid virologic response and complete early virologic response with IDX184, pegylated interferon and ribavirin in genotype 1 HCV-infected subjects: interim analysis. *Hepatology* 2012;56:1006A.
86. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral janus kinas inhibitor. In patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2014;9:1485-93.
87. Younossi Zm, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of Non-alcoholic steatohepatitis: Interim analysis from a multicenter, placebo-controlled phase 3 trial. *Lancet* 2019;394:2184-96.

REVIEW ARTICLES/EDITORIALS:

1. Goff JS. Pancreatic exocrine function testing. *Western J Med* 1981;135:368-74.
2. Goff JS. Diagnosis and evaluation of esophageal disorders. *Ear Nose Throat J* 1984;63:29/19-42/26.
3. Goff JS. Acute diarrhea in the United States: etiology and overview. *Excerta Medica* 1986.
4. Benjamin SB, Goff JS, Hacksaw BT. Chest pain: cardiac or esophageal? *Patient Care*, July 15, 1987;116-32.
5. Goff JS. Infectious causes of esophagitis. *Ann Rev Med* 1988;39:163-9.
6. Goff JS. The human sphincter Oddi: physiology and pathophysiology. *Arch Int Med* 1988;148:2673-7.
7. Goff JS. Early detection of esophageal cancer. *Rose Medical Center Cancer Monograph*, 1987.
8. Goff JS. Diagnosis and treatment of reflux esophagitis. *Modern Medicine* 1989;57:92-103.
9. Goff JS. CA 19-9 and the diagnosis of pancreatic cancer. *Rose Medical Center Cancer Monograph*, 1988.
10. Goff JS. The tight esophagus - bougie or balloons. *Canadian J Gastroenterology* 1990;4:593-5.

11. Goff JS. Endoscopic variceal ligation. Canadian J Gastroenterology 1990;4:639-42.
12. Goff JS. Emergency: Upper gastrointestinal bleeding. Hospital Medicine 1992;28:119-31.
13. Goff JS. Percutaneous gastrostomy and jejunostomy: lessons from the first decade. Canadian J Gastroenterology 1992;6:149-54.
14. Goff JS. Endoscopic variceal ligation for treatment of bleeding varices. Canadian J Gastroenterology 1992;6:213-17.
15. Goff JS. Endoscopic sclerotherapy for esophageal and gastric varices: safety and efficacy. Endoscopy 1994;26:483-5.
16. Bonci L, Fasano A, Goff JS, Nelson AM. Malabsorption syndromes. Patient Care 1998;
17. Goff JS. Endoscopic variceal ligation - I. UpToDate 1999 present.
18. Goff JS. Treatment of gastric varices in 2004: Is there a role for endoscopy? Visible Human Journal of Endoscopy 2004;4
19. Goff JS. Endoscopic variceal ligation safety throughout the GI tract. Gastrointest Endosc 2005;62:228-9.
20. Goff JS. Endoscopic treatment of bleeding esophagogastric varices: what really matters? Gastrointest Endosc 2008;67:828-9.

LETTERS TO THE EDITOR/CRITIQUES/BOOK REVIEWS:

1. Goff JS. Saline lavage for colonoscopy. Gastroenterology 1982;83:524. Letter to the Editor.
2. Heilman J, Goff JS. Case 50-1982: Familial polyposis of the colon and extracolonic tumors. N Engl J Med 1983;308:906-7. Letter to the Editor.
3. Goff JS, Satterlee W. Sucralfate and esophageal ulcers. Gastrointest Endosc 1985;31:50. Letter to the Editor.
4. Goff JS. Treatment of diabetic diarrhea with lidamidine hydrochloride. Ann Int Med 1984;101:874-5. Letter to the Ed.
5. Goff JS. Book Review: Endoscopic Interpretation. Normal and

- Pathologic Appearances of the Gastrointestinal Tract. Michael O. Blackstone, Ed. Raven Press, NY, 1984. Arch Surgery 1985;120:505.
6. Goff JS, Perino LE, Stiegmann GV. Roux-en Y syndrome. Gastroenterology 1985;89:703. Letter to the Editor.
  7. Goff JS. Book Review: Therapeutic Gastrointestinal Endoscopy. Stephen E. Silvas, Ed. Igaku-Shoin, New York, 1985. Arch Surg 1985.
  8. Goff JS. Book Review: Inflammatory Bowel Disease 1986. Daniel Rachmilewitz, Ed. Martinus Nijhoff Publishers, Dordrecht, 1986. Arch Surg, 1986.
  9. Goff JS. Book Review: Endoscopic Laser Surgery Handbook. New York, 1987. Arch Surg, 1987.
  10. Goff JS. Book Review: Surgical Application of Lasers. Second Ed. John A. Dixon, Ed. Tear Book Medical Publishers, Inc., Chicago, 1987. Arch Surg, 1987.
  11. Goff JS. Commentary on: Morressey and Reichelderder. Gastrointestinal Endoscopy. NEJM 1991;325: 1142-9 and 1214-22. in Abstracts of Clinical Care Guidelines 1992;4:6-7.
  12. Goff JS. Book Review: Baille J. Gastrointestinal Endoscopy. Basic Principles and Practice. Butterworth-Heinemann Ltd., Oxford, 1992. Am J Gastro, 1992.
  13. Goff JS. Book Review: Cotton PB, Tytgat GNJ, Williams CB. Annual of Gastrointestinal Endoscopy. Current Science Ltd., London, 1992. Am J Gastro, 1992.
  14. Goff JS. Response to Drs. Lehman and Sherman. Modification of common bile duct pre-cut sphincterotomy. Gastrointestinal Endoscopy 1996;43:80-1.
  15. Goff JS. Response to Dr. Prakash. Transpancreatic sphincter approach to biliary sphincterotomy. Gastrointestinal Endoscopy 1996;44:510.
  16. Goff JS. Response to Dr. Rolny. Is endoscopic common bile duct stenting useful in patients with suspected sphincter of Oddi dysfunction. Am J Gastro 1997;92:2134. Letter to the Editor.
  17. Goff JS. Book Review: Charlotte Stendal. Practical Guide to Gastrointestinal Function Testing. Blackwell Science, Oxford, 1997. Gastrointestinal Endoscopy, 1998.

18. Goff JS. Book Review: Michael Sivak, Jr. Gastrointestinal Endoscopy (CD-ROM), W.B. Saunders, 1999. *American Journal of Gastroenterology*, 2000.

INVITED REVIEWER:

Journals:

1. *Gastroenterology*
2. *Digestive Diseases and Sciences*
3. *Western Journal of Medicine*

4. Annals of Internal Medicine
5. Digestive Diseases
6. Patient Care
7. American Journal of Gastroenterology - Associate Ed. 1991-present.
8. American Review of Respiratory Disease
9. Endoscopy
10. Gastrointestinal Endoscopy
11. Journal of Clinical Gastroenterology
12. Alimentary Pharmacology and Therapeutics
13. Journal of Medical Economics

Organizations:

1. Veterans Administration
2. NIH (grants and site visitor)
3. NIH- SBIR (1993 - present)
4. The Center for Personalized Education for Professionals (current)



INVITED LECTURES:

1. International Symposium on Diarrheal Syndromes and Functional Gastrointestinal Disorders: Lidamidine hydrochloride. Acapulco, Mexico, January, 1984.
2. United States Air Force Academy Hospital Symposium on Emergency Medicine. Monarch, CO, February, 1984.
3. Colorado Academy of Family Physicians. Breckenridge, CO, July, 1984.
4. Medical-Surgical Gastroenterology City-Wide Conference. Veterans Administration Hospital, Portland, OR, October, 1984.
5. Colorado Society of Radiologic Technologists 53rd Annual Meeting. Vail, CO, May, 1986.
6. Southwestern Surgical Congress' Scientific Session. Denver, CO, September, 1986.
7. American Society for Gastrointestinal Endoscopy Fourth National Postgraduate Course. Washington, D.C., January, 1987.
8. Rocky Mountain Society of Gastrointestinal Assistants Winter Education Course. Keystone, CO, February, 1988.
9. National Society of Gastrointestinal Assistants Annual Meeting. New Orleans, LA, May, 1988.
10. Department of Clinical Pharmacology Research Conference, University of Berne. Berne, Switzerland, July, 1988.
11. Department of Gastroenterology Research Conference, University of Berne. Berne, Switzerland, July, 1988.
12. Division of Gastroenterology Research Conference, University of Arizona. Tucson, AZ, December, 1988.
13. National Society of Gastrointestinal Assistants Annual Meeting. Washington, D.C., May, 1989.
14. Medical Grand Rounds, St. Anthony Hospital. Denver, CO, June, 1989.
15. American College of Gastroenterology Postgraduate Course. New Orleans, LA, October, 1989.

16. Fourth International Course on Therapeutic Endoscopy. Toronto, Canada, October, 1989. Variceal ligation and PEG.
17. Colorado Society of Gastrointestinal Nurses and Assistants Meeting. Glenwood Springs, CO, March, 1990.
18. ASGE Postgraduate Course (Digestive Disease Week). San Antonio, TX, May, 1990.
19. Rocky Mountain Chapter of the American Liver Foundation Seminar. Denver, CO, June, 1990.
20. Gastrointestinal Motility Symposium (Sandhill Scientific). Vail, CO, August, 1990. Course director.
21. Texas Society for Gastrointestinal Endoscopy Annual Course. Austin, TX, September, 1990.
22. Baylor University, Division of gastroenterology, Department of Medicine. Houston, TX, November, 1990. Visiting professor.
23. 1991 Clinical Updates in the Treatment of Gallstone Disease. Breckenridge, CO, January, 1991. Course director.
24. ASGE Postgraduate Course (Digestive Disease Week). New Orleans, LA, May, 1991. Endoscopic management of varices.
25. 1991 Clinical Updates in Gallstone Disease. Sacramento, CA, June, 1991. Course director.
26. Southern California Society of Gastrointestinal Endoscopy. Los Angeles, CA, June, 1991. Variceal ligation.
27. Advancing Gastroenterology into the 1990's. Vail, CO, July, 1991. Course director.
28. Fifth International Course on Therapeutic Endoscopy. Toronto, Canada, October, 1991. Variceal ligation and PEG.
29. Fitzsimons Army Medical Center. Aurora, CO, February, 1992. Visiting consultant.
30. American College of Gastroenterology Regional Postgraduate Course. Scottsdale, AZ, February, 1992. Management of portal hypertension.
31. Advanced Therapeutic Endoscopy XI. Miami, FL, March, 1992.

Endoscopic treatment of bleeding varices.

32. Techniques of Endoscopic Therapy in Gastrointestinal Diseases. Washington, D.C., April, 1992. Variceal ligation.

33. Sixth International Course on Therapeutic Endoscopy. Toronto, Canada, October, 1992. Variceal ligation and PEG.

34. Henry Ford Hospital Gastroenterology Division. Detroit, MI, November, 1992. Visiting professor.

35. Michigan Society for Gastrointestinal Endoscopy. Detroit, MI, November, 1992.

36. XIth International Workshop on Diagnostic and Operative Digestive Endoscopy, American Hospital of Paris. Paris, France, December, 1992. Variceal ligation.

37. Advanced Therapeutic Endoscopy XII. Miami, FL, March, 1993. Endoscopic management of varices and PEG.

38. IXth Digestive Diseases at the Caribbean. San Juan, PR, March, 1993. Endoscopic management of varices and management of ascites and PHG.

39. Rocky Mountain Society of gastrointestinal Nurses and Assistants Spring 1993 Seminar. Denver, CO, March, 1993.

40. Midwest American College of Gastroenterology Regional Course. Indianapolis, IN, April, 1993. Management of varices and PHG.

41. University of California at San Francisco. San Francisco, CA, April, 1993. Visiting professor.

42. 4th International Conference on Digestive Diseases. Erlangen, Germany, June, 1993. Variceal ligation and sclerotherapy.

43. Hamburger Arbeitsgemeinschaft fur Gastroenterologie. Hamburg, Germany, June, 1993. Invited lecturer - variceal ligation.

44. Rhein-Main-Arbeitsgemeinschaft fur Gastroenterologie. Frankfurt, Germany, June, 1993. Invited lecturer - variceal ligation.

45. Second International Conference in Gastroenterology. Hong Kong and Chengdu, China, August, 1993. Variceal bleeding and esophageal stricture management.

46. American College of Gastroenterology Breakfast Symposium, ACG Annual meeting. New York, NY, October, 1993. Treatment of varices.
47. Seventh International Course on Therapeutic Endoscopy. Toronto, Canada, October, 1993. Variceal ligation and PEG.
48. 19th Annual Postgraduate Course of the New York Society for Gastrointestinal Endoscopy. New York, NY, November, 1993.
49. Maadi Army Hospital and Bilharzia Institute. Cairo, Egypt, November, 1993. Invited lecturer - endoscopic treatment of varices.
50. University of Alexandria Hospital. Alexandria, Egypt, November, 1993. Invited lecturer - endoscopic treatment of varices.
51. 16th Annual Hepatology-Gastroenterology Weekend Retreat, Southern California Society of Gastroenterology. San Diego, CA, November, 1993.
52. Region V American College of Gastroenterology Regional Postgraduate Course. Snowmass, CO, January, 1994. Course director.
53. University of Alberta and University Hospital. Edmonton, Canada, March, 1994. Visiting endoscopy professor.
54. The Annual Ferguson Lectureship, Bethany Medical Center. Kansas City, Kansas, April, 1994. Gastrointestinal bleeding.
55. University of Michigan Gastroenterology Division. Ann Arbor, MI, April, 1994. Visiting professor. Sphincter of Oddi manometry.
56. Family Medicine Department Grand Rounds, Northern Colorado Medical Center. Greeley, CO, June, 1994. Motility disorders of the GI tract.
57. Falk Symposium No. 79, Portal Hypertension. Freiberg, Germany, June, 1994. Variceal ligation.
58. Vth Curso International de Endoscopia Diagnostica e Therapeutica. Sao Paulo, Brazil, July, 1994. Variceal ligation.
59. Grand Rounds, St. Anthony Hospital. Denver, CO, December, 1994. H. pylori.
60. Third Annual Pre-Derby Gastroenterology Conference, University of Louisville. Louisville, KY, April, 1995. Endoscopic treatment of esophageal varices.

61. ASGE Annual Postgraduate Course (Digestive Diseases Week). San Diego, CA, May, 1995. Management of variceal bleeding; Biliary and esophageal stenting.
62. Meet the Professors Lunch (Digestive Disease Week). San Diego, CA, May, 1995. Variceal bleeding.
63. Kentucky Society for Gastrointestinal Endoscopy Annual Meeting, University of Kentucky. Lexington, KY, September, 1995. Endoscopic management of variceal bleeding.
64. Eighth International Course on Therapeutic Endoscopy. Toronto, Canada, October, 1995. Variceal ligation.
65. Internal Medicine Grand Rounds and Gastroenterology Division Conference, University of Maryland School of Medicine. Baltimore, MD, November, 1995. Management of GERD and variceal hemorrhage.
66. Center for Advanced Surgical Technology, Good Samaritan Health System. San Jose, CA, December, 1995. Co-course director - variceal ligation.
67. American College of Gastroenterology Governor's Postgraduate Course. Phoenix, AZ, February, 1996. Portal hypertension and endoscopic management of bleeding varices.
68. Medical Grand Rounds, Fitzsimons Army Medical Center. Aurora, CO, March, 1996. Management of acute pancreatitis.
69. Northeast Ohio Society for Gastrointestinal Endoscopy Meeting. Akron, OH, March, 1996. Management of variceal hemorrhage.
70. Colorado State Society of Gastrointestinal Nurse and Assistants Meeting. Fort Collins, CO, March, 1996. AIDS and the GI tract.
71. Recent Advances in Diseases of the Liver, Pancreas and Biliary Tree, Lahey-Hitchcock Clinic. Seabury Resort, Cape Cod, MA, September, 1996. Endoscopic management of variceal hemorrhage.
72. Gastrointestinal Grand Rounds, Northwestern Memorial Hospital, Northwestern University. Chicago, IL, October, 1996. Variceal bleeding.
73. ASGE 13th Interim Postgraduate Course, GI Bleeding: Critical Decision Making. New York, NY, March, 1997. Esophageal and gastric variceal hemorrhage management; GI telangiectasias.
74. American College of Gastroenterology Regional Postgraduate

Course. Palm Springs, CA, April, 1997. RUQ pain, obscure GI bleeding, pancreatic pseudocyst management, endoscopic management of variceal bleeding.

75. Oklahoma Gut Club Meeting. Oklahoma City, OK, April, 1997. Endoscopic management of variceal bleeding.

76. American College of Gastroenterology Annual Postgraduate Course. ACG annual meeting Chicago, IL, November, 1997. Portal Hypertension.

77. American College of Gastroenterology Governor's Postgraduate Course "Back to Basics II" Phoenix, AZ, February, 1998. Portal hypertension; Treatment of variceal bleeding.

78. Brigham and Women's/Utah Therapeutic GI Endoscopy Course 1998. Park City, Utah, February, 1998. Treatment of variceal bleeding; Manage of the bile duct stricture.

79. Texas Tech University Health Sciences Center, El Paso, TX. Visiting professor. March, 1999. Treatment of bleeding in patients with portal hypertension; ERCP: Questions and current answers.

80. Update in Gastroenterology, Colorado Springs, CO (sponsored by Memorial Hospital). June, 1999. Evaluation and treatment of lower GI bleeding; Colon cancer screening and recommendations for colon polyps follow-up.

80. The impact of the COX2 inhibitors on gastroenterology. Denver, CO. Coors Field) June, 1999.

81. University of Colorado City-Wide GI Conference, Denver, CO, October, 1999. Pre-cut sphincterotomy.

82. Community Hospital, Grand Junction, CO, November, 1999. Prokinetic Drugs: Role in gastrointestinal disorders.

83. New York Society for Gastrointestinal Endoscopy Postgraduate Course, November 18-19, 1999. New York City, NY. Pre-cut sphincterotomy and Portal hypertensive bleeding: inject, band or glue?

84. Crohn's and Colitis Conference, Rose Medical Center, Denver, CO, March 11, 2000. Medical Treatment of Inflammatory Bowel Disease.

85. Colorado Plains Medical Center, Ft. Morgan, CO, October 13, 2000. Update on Diagnosis and Treatment of Hepatitis C.

86. Rocky Mountain SGNA meeting and course, Denver, CO, October 14,

2000. Stretta Procedure vs Endoscopic Sewing (BESS) for GERD.
87. Rocky Mountain ALF Chapter "Liver Update Spring 2001", Denver, CO, April 21, 2001. New Treatment for Hepatitis C.
88. Digestive Disease Clinic Symposium, Colorado Springs, CO, September 28, 2001. Stretta procedure for treating GERD.
89. American Liver Foundation Hepatitis C Seminar, Colorado Springs, CO, March, 2002.
90. Rocky Mountain SGNA meeting and course, Denver, CO, March, 2003. Non-surgical methods for treating GERD.
91. AASLD/ASGE pre-annual meeting course, Treatment of Gastric Varices in the US. Boston, MA, October, 2003.
92. CCFA Crohn's Update, Fort Collins, CO, May, 2004.
93. ALF Liver Update, St. Antony's Hospital, Denver, CO, June, 2004.
94. CCFA IBD Research Update, Colorado Springs, CO, August, 2004.
95. Medical Grand Rounds, Presbyterian-St. Luke's Hospital, Gastrointestinal Motility Disorders, Denver, CO, January, 2005.
96. Creativity and Madness meeting, A Psychological Study of the Poet Jose Marti and His Influence On the US and Cuba, Santa Fe, NM, February, 2005.
97. ALF Liver Update, Non-Alcoholic Steatohepatitis, Denver, CO, June, 2005.
98. Propofol Training Course, History of Sedation for Endoscopy and Propofol Experience at SAC, St. Anthony's Hospital, Denver, CO, April, 2006 and November, 2006.
99. Endoscopic Clipping Update, Cheyenne Mountain Resort, Colorado Springs, CO, June, 2006 and Albuquerque, NM March, 2007.
100. Creativity and Madness meeting, A Psychological Study of the Poet Jose Marti and His Influence on the US and Cuba, Santa Fe, NM, August, 2006.
101. Visiting Professor talks, Propofol Sedation for Endoscopy, Control of Variceal Bleeding, and Hepatitis C Update, SMDC Medical

Center, Duluth, MN October, 2006.

102. Rocky Mountain SGNA meeting, Esophageal Cancer and Stenting, Boulder, CO, October, 2006.

103. Propofol Training Course, History of Sedation for Endoscopy and Propofol Experience at SAC, Lutheran Medical Center, Wheat Ridge, CO, June, 2007.

104. Iowa City Clinic, Amitiza, Des Moines, IO, June, 2007.

105. St. Peter's Hospital Helena, MN, and Deaconess Medical Center, Spokane, WA, Use of Endoscopic Stents, January, 2008.

106. Colorado Department of Corrections, Management of Hepatitis C, Limon, CO, March, 2008.

107. Creativity and Madness meeting, Niccolo Paganini: Possessed, Mad or Just Ugly (Possible Bipolar Disorder), Santa Fe, NM, August, 2008.

108. CCFA Conference at University of Colorado, Medical treatment of Crohn's Disease, Aurora, CO, April, 2009.

109. Medical Grand Rounds, Endoscopic Ultrasonography, Medical Center of Aurora, Aurora, CO, April, 2009.

110. National Annual SGNA meeting, Non-alcoholic Steatohepatitis, Indianapolis, Indiana, May, 2011.

111. Creativity and Madness meeting, Creativity, Boston, MA, October, 2011.

112. Creativity and Madness meeting, Creativity, Santa Fe, NM, August, 2012.

113. Third Annual Interactive Symposium for Clinicians, Nonalcoholic Steatohepatitis, Denver, CO, 2012.

114. Creativity and Madness meeting, The 27 Club: Theory and Facts, Bethesda, MD, October, 2013.

115. Gut Club, Cellvizio: Overview, Denver, CO, January, 2013.

116. Rocky Mountain Interventional Endoscopy 2014, Anorectal Disease management for the Gastroenterologist, Aurora, CO, February, 2014.

117. Gut Club, Hot Topics in Colon Cancer, Denver, CO, June, 2015.



118. Rocky Mountain SGNA annual meeting, Marijuana and Gastroenterology; Liver Function Test and Liver Diseases Lakewood, CO, September, 2015 and RMPANA monthly meeting, March, 2016.

PHARMACEUTICAL SPEAKER BUREAUS:

1. Gilead
2. Intercept
3. Bristol-Myers-Squibb
4. AbbVie
5. Santaris

GRANTS AND RESEARCH CONTRACTS:

1. Kroc Foundation: Study of diabetic diarrhea. 1980
2. Miles Laboratory: Acarbose and dumping syndrome. 1980
3. William H. Roher, Inc.: Lidamide and irritable bowel. 1982
4. William H. Roher, Inc.: Lidamide and chronic diarrhea. 1983
5. Hoffman-LaRoche, Inc.: Trimoprostil and bile reflux gastritis. 1983
6. Veterans Administration VA CSP #237 - Participating Investigator: Sclerotherapy for esophageal varices. 1985-90
7. American Society for Gastrointestinal Endoscopy: The role of the sphincter of Oddi in alcoholic pancreatitis. 1986
8. Veterans Administration VA CSP #277 - Participating Investigator: A prospective randomized trial of medical vs surgical therapies for gastroesophageal reflux disease. 1986-89
9. Eli Lilly and Co.: Nizatidine clinical investigations. 1986, 1988
10. Syntex, Inc.: Enprostil clinical investigations. 1986, 1987
11. Hoffman-LaRoche, Inc.: Flumazenil clinical investigation. 1986
12. Sandoz, Inc.: Effect of cisapride on idiopathic gastroparesis. 1989
13. G. D. Searle and Co.: Efficacy of misoprostol for NSAID induced UGI symptoms and gastric ulcer. 1989
14. Proctor and Gamble: Treatment of UGI lesions with Denol. 1989
15. American Cyanide: Photophyrin II therapy for esophageal cancer. 1989 (shared with Dept. Surgery)
16. Takeda-Abbott: Lansoprazole for reflux and DU. 1989
17. Schering Corp.: Interferon therapy for chronic hepatitis C. 1989.
18. Poudre Valley Hospital Foundation: Effect of propofol on human sphincter of Oddi. 1993.

19. Janssen Research Foundation: Cisapride for gastroesophageal reflux disease. 1995.
20. TAP Holding Inc.: Lansoprazole and clarithromycin or ampicillin for Helicobacter pylori eradication. 1995.
21. Astra Merck: Omeprazole, clarithromycin, and amoxicillin for Helicobacter pylori positive duodenal ulcers. 1996
22. G. D. Searle C.: Arthrotec 75 vs nambumetome and naproxen for osteoarthritis. 1997
23. ISIS Pharmaceuticals: ISIS 2302, human ICAM-1 antisense phosphorothioate oligonucleotide, for treatment of Crohn's disease. 1997
24. Schering-Plough Corp.: Interferon and ribavirin for non-responder or relapsing hepatitis C. 1997
25. Schering-Plough Corp.: Interferon and ribavirin for naive hepatitis C. 1998
26. ICOS Corporation/Parexel: rPAF-AH for prevention of post-ERCP pancreatitis. 1998
27. Amgen: Treatment of hepatitis C non-responders and relapsers with Imfergen. 1999
28. Schering-Plough Corp.: IL-10 for prevention of post-ERCP pancreatitis. 1999
29. GlaxoWellcome: Alosetron in male subjects with irritable bowel syndrome. 1999
30. GlaxoWellcome: Alosetron in female patients with alternating bowel movement pattern IBS. 1999
31. Novartis: Tegaserod for constipation predominant irritable bowel syndrome. 1999
32. Conway: The Stretta procedure for treatment of GERD. 1999
33. Genetics Institute: Il-11 for treatment of Crohn's disease. 2000
34. Glaxo-Welcome: Alosetron for treatment of diarrhea predominant IBS. 2000
35. Schering Corp.: Fellowship Program in Liver Diseases for

Physician Assistants. 2000

36. Synsorb Corp.: Treatment of recurrent C. difficile associated diarrhea with SYNORB Cd. 2000
37. Schering Corp.: Treatment and Retreatment of Hepatitis C with PEG-interferon and ribavirin. 2000
38. Roche: Treatment of hepatitis C with pegylated interferon apha-2a and ribavirin. 2000
39. Otsuka America Pharmaceuticals: Treatment of ulcerative colitis with OPC-6535 tablets. 2000
40. Schering Corp.: Treatment of high-risk cirrhotic patients with HCV with PEG-interferon and ribavirin. 2000
41. AstraZenica: Treatment of GERD patients with esomeprazole. 2000
42. Incara: Low molecular weight heparin for ulcerative colitis. 2000
43. Celltech: Humanized anti-TNF-alpha (CDP571) for Crohn's disease. 2000
44. Wyeth-Ayrest: Pantoprazole intravenously for preventing rebleeding after hemostasis has been achieved for bleeding ulcers. 2001
45. ISIS Pharmaceuticals: ISIS 2302 (ICAM-1 inhibitor) for Crohn's Disease Phase 2 and Phase 3 trials. 2001
46. Procter and Gamble: High dose Asacol (5-ASA) for ulcerative colitis. 2001
47. Novartis: Tegaserod for non-ulcer dyspepsia with or without delayed gastric emptying. 2001
48. Elan: Antegren (natalizumab) for moderate to severe active Crohn's disease. 2001
49. Schering-Plough: Recombinant human interleukin-10 (Tenovil) to prevent post ERCP pancreatitis. 2001
50. Forest Lab: Dexloiglumide for constipation predominant IBS. 2002
51. Forest Lab: Dexloiglumide for females with constipation

predominant IBS. 2002.

52. Solvay Pharmaceuticals: Cilansetron for diarrhea predominant IBS. 2001

53. Janssen-Eisai Pharmaceuticals: Rabeprazole vs omeprazole for GERD. 2002

54. SmithKline Beecham: NK-3 receptor antagonist for IBS pain (safety and efficacy). 2002

55. ISIS: Alicaforsan (ISIS 2302) infusions for Crohn's disease. 2002

56. Abbott: Human monoclonal antibody (Adalimumab) for the induction and maintenance in Crohn's disease. 2002

57. Novartis: Tegaserod for females with constipation predominant IBS. 2002

58. Novartis: Tegaserod for dyspepsia with and without gastroparesis. 2002

59. Wyeth: Dose ranging study of recombinant human interleukin-11 for Crohn's disease. 2002

60. GlaxoSmithKline: Dose ranginf study of SB223412 for patients with IBS. 2002.

61. Elan: Natalizumab (Antegren) for maintenance of clinical response in Crohn's disease. 2003

62. Idenix Pharmaceuticals: L-dT (telbivudine) vs lamivudine for hepatitis B. 2003

63. NPS Allelix Corp: ALX-0600 for moderately active Crohn's disease. 2003

64. Fujisawa: FK788 (PGI<sub>2</sub> agonist) for treatment of hepatitis C. 2003.

65. ISIS: Alicaforsan (ISIS 2302) enema for ulcerative colitis. 2003.

66. Otsuka: OPC-6535 for active ulcerative colitis and maintenance of remission. 2003

67. Shire: SPD476 (mesalamine) for ulcerative colitis. 2003

68. Schering/Amgen: Darbepoetin and Neupogen for supportive treatment of HCV with PEG-IFN/ribavirin (KATT Trial) 2003
69. GlaxoSmithCline: SB683699 for Crohn's disease. 2003
70. AstraZeneca: AZD0865 vs esomeprazole for GERD with and without erosions. 2003
71. Sucampo/PRA: Oral RU-0211 for treatment of constipation; open label safety study. 2003
72. Valeant: Viramidine vs ribavirin in combination with PEG-IFN for hepatitis C. 2004
73. ChemoCentryx: CL003-282 for Crohn's disease. 2004
74. ISIS Pharmaceuticals: ISIS 14803 for hepatitis C not responding to PEG-IFN and ribavirin. 2004
75. Elan: Natalizumab for moderate and severe Crohn's disease patients with elevated CRP. 2004
76. GlaxoSmithKline: Talnetant for patients with IBS pain. 2004
77. Otsuka: OPC-6535 vs Asaol for maintenance of remission in patients with ulcerative colitis. 2004
78. AstraZeneca/ICON: AZD0865 vs esomeprazole for erosive and non-erosive esophagitis. 2004
79. Abbott: Long-term safety and tolerability of adalimumab for patients with Crohn's disease. 2004
80. Centocor: Remicade vs azathioprine for Crohn's disease (SONIC Trial). 2005
81. Berlex: Sargramostim (Leukine) for treatment of active Crohn's patients and for those who have responded to sargramostim. 2005
82. Alizyme: Renzipride for constipation predominant IBS in women. 2005
83. Otsuka: Adacolumn apheresis system for the treatment of moderate to severe ulcerative colitis. 2005
84. Otsuka: Adacolumn apheresis system for the treatment of moderate to severe Crohn's diseases. 2005

85. AstraZeneca: Investigation of the prevalence of clinically relevant esophageal mucosal pathology. 2005
86. ARYx: ATI-7505 for treating erosive or non-erosive esophagitis. 2005
87. TAP Pharmaceutical: TAK-390MR vs placebo for non-erosive gastroesophageal reflux. 2005
88. TAP Pharmaceutical: TAK-390MR vs lansoprazole for healing erosive esophagitis and maintenance of healing. 2005
89. UCB: Certolizumab pegol for Crohn's disease, assess corticosteroid sparing effect. 2006
90. Alamo Medical Research: Valopicitabine (NM283) plus peginterferon for naïve genotype 1 hepatitis C. 2006
91. TAP Pharmaceutical: TAK-390MR vs placebo for maintenance of healing in patients with erosive esophagitis. 2006
92. Tap Pharmaceutical: TAK-390MR vs placebo to evaluate the safety and efficacy in patients with non-erosive gastroesophageal reflux disease. 2006
93. Otsuka: Evaluation of the durability of response to treatment with the adacolumn apheresis system for patients with moderate ulcerative colitis and Crohn's disease. 2006
94. Abbott: Adalimumab for Crohn's patients with previous exposure and failure to infliximab. 2006
95. Tioga/RTI Health Solutions: Asimadoline vs placebo for treatment of IBS. 2006
96. Theravance: TD-5108 vs placebo for chronic constipation. 2006
97. Abbott: Adalimumab for induction and maintenance of patients with moderate to severe ulcerative colitis. 2006
98. Valeant: Taribavirin and peginterferon alpha-2b vs ribavirin and peginterferon alpha-2b for hepatitis C. 2007
99. Horizon: HZT-501 to prevent gastrointestinal complications of NSAID's. 2007
100. Prometheus: Procurement of blood samples for development of

gastrointestinal disease panel. 2007

101. Centocor: Golimumab for moderate and severe ulcerative colitis. 2007

102. Cerimon: Basiliximab and corticosteroids for steroid refractory ulcerative colitis. 2007

103. Bristol-Myers-Squibb: Abatacept vs placebo for patients with ulcerative colitis who have failed conventional therapy. 2007

104. Osiris Therapeutics: Prochymal (Ex vivo cultured human mesenchymal stem cells) vs placebo for treatment refractory moderate to severe Crohn's disease. 2007

105. UCB: Long term safety maintenance of response with certilizumab pegol for Crohn's disease. 2008

106. Biogen Idec: Avonex for moderate to severe ulcerative colitis. 2008

107. Sucampo: Lubiprostone for opioid-induced constipation. 2008

108. Hollis-Eden: HE3286 for mild to moderate ulcerative colitis. 2008

109. Centocor: Ustekinumab for moderate to severe Crohn's disease that has previously failed anti-TNF therapy. 2008

110. Gilead: GS-9450 for nonalcoholic steatohepatitis (NASH). 2008

111. COSMO: Budesonide-MMX for mild to moderate ulcerative colitis (induction of remission and maintenance). 2008

112. Otsuka: An observational prospective study to identify clinical, endoscopic, and/or biological predictors that correlate with histopathologic findings in subjects with moderate to severe ulcerative colitis. 2008

113. Pfizer: CP-690,550 vs placebo for moderate to severe Crohn's disease. 2008

114. Eisai: Rabeprazole vs esomeprazole for healing and symptomatic relief in patients with moderate to severe erosive esophagitis. 2008

115. Eisai: Rabeprazole vs esomeprazole for healing and symptomatic relief in patients with mild to moderate erosive esophagitis. 2008



116. Eisai: Rabeprazole vs ranitidine for maintenance of healed erosive esophagitis. 2008
117. Forest Laboratories: Linaclotide vs placebo for patients with chronic constipation. 2008
118. Forest laboratories: Linaclotide open label long-term safety in patients with chronic constipation or constipation predominant IBS. 2008
119. Eisai: Evaluation of the long-term safety and efficacy of rabeprazole vs placebo for subjects with symptomatic GERD. 2009
120. Millennium: Vedolizumab (MLN0002) for moderate to severe Crohn's disease (induction of remission and maintenance) 2009
121. Millennium: Vedolizumab (MLN0002) long term efficacy and safety for patients with ulcerative colitis and Crohn's disease. 2009
122. XenoPort: Arbaclofen placarbil (XP19986) adjunctive therapy for GERD subjects who are incomplete responders to PPI's. 2009
123. Furiex: JNJ27018966 for treating patients with IBS-D. 2010
124. Ferring: Pentasa sashays for maintenance of Crohn's disease. 2010
125. GSK: CCX Oral chemokine receptor (CCR9) antagonist for treating Crohn's disease (3 protocols. 2010
126. Pfizer: Anti-IL-6 antibody for treating Crohn's patient's who are refractory to anti-TNF medications. 2010
127. NovoNordisk: Monoclonal IgG4 antibody[NN8555 anti-NKG2D (natural killer cells)]for treating Crohn's disease. 2011
128. Pfizer: Stem cells for treatment of severe ulcerative colitis unresponsive to all other treatment options. 2011
129. Idenix: IDX184 (nucleotide prodrug) in combination with PEG-IFN and ribavirin for treatment naïve HCV patients. 2011
130. Tsumura: A multicenter, randomized, double-blind, placebo controlled study of Daikenchuto (TU-100)for subjects with moderate Crohn's disease. 2011.
131. Abbott: A randomized open-label study to evaluate he safety and efficacy of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333

coadministration with ribavirin(RBV)in adults with genotype-1 chronic hepatitis C virus (HCV) infection and cirrhosis. 2012.

132. Abbott: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 co-administration with ribavirin(RBV) in treatment-experienced adults with genotype 1 chronic hepatitis c virus (HCV) infection. 2012.

133. Avaxia Biologics: A multicenter, double-blind, placebo-controlled, ascending-dose, repeat-dose safety and pharmacokinetic investigation of a delayed-release, enteric-coated capsule formulation of AVX-140[anti-TNF 9tumor necrosis factor) globulin (bovine) in patients with active ulcerative colitis. 2013.

134. AstraZeneca/MedImmune Limited: A phase 2a study of the efficacy and safety of MEDI2070 in subjects with moderate to severe Crohn's disease who have failed or are intolerant to anti-tumor necrosis factor-alpha therapy. 2013.

135. Intercept: A phase 3, double blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of obeticholic acid in subjects with non-alcoholic steatohepatitis. 2016.

136. Gilead: A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib in subjects with non-alcoholic steatohepatitis and bridging fibrosis (F3). 2017.

137. Gilead: A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis. 2017.

138. Tobira Therapeutics: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of cenicriviroc for the treatment of liver fibrosis in adult subjects with non-alcoholic steatohepatitis. 2018.

139. Phantom Pharmaceuticals: A phase 3, randomized, double-blind, two-phase, multicenter study to evaluate the efficacy and safety of vonoprazan 20 mg compared to lansoprazole 30 mg for healing in patients with erosive esophagitis and to evaluate the efficacy and safety of vonoprazan (10 mg and 20 mg) compared to lansoprazole 15 mg for the maintenance of healing in patients with healed erosive esophagitis. 2019.

140. Phantom Pharmaceuticals: A phase 3, randomized, multicenter

study to evaluate the efficacy and safety of open-label dual therapy with oral vonoprazan or double-blind triple therapy with oral vonoprazan 20 mg compared to double-blind triple therapy with oraoijhkgijuhgfl lansoprazole 30 mg daily in patients with *Helicobacter pylori* infection. 2019.

140. Braintree Laboratories: Double-blind, randomized, Two-phase, active-controlled study to evaluate the efficacy and safety of tegoprazan inn patients with non-erosive and erosive esophagitis. 2022